MNPR · Monopar Therapeutics
$105.90
-5.22 (-4.70%)
At close · Jul 20
Market Cap
$709.43M
Shares
6.70M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Chandler D. Robinson | CEO | $10,637,821 |
| Andrew J. Cittadine | COO | $4,706,431 |
| Quan Vu | CFO | $2,101,314 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Chandler D. Robinson | CEO | $1,144,480 |
| Andrew J. Cittadine | COO | $554,796 |
| Karthik Radhakrishnan | CFO | $320,160 |
| Quan Vu | CFO | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Chandler D. Robinson | CEO | $1,778,667 |
| Andrew J. Cittadine | COO | $911,161 |
| Kim R. Tsuchimoto | CFO | $848,441 |
| Karthik Radhakrishnan | CFO | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Chandler D. Robinson | CEO | $1,601,448 |
| Andrew J. Cittadine | COO | $752,326 |
| Kim R. Tsuchimoto | CFO | $695,128 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Chandler D. Robinson | CEO | $1,588,564 |
| Andrew P. Mazar | Board Member | $872,571 |
| Kim R. Tsuchimoto | CFO | $523,349 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Chandler D. Robinson | CEO | $541,250 |
| Andrew P. Mazar | Board Member | $465,500 |
| Kim R. Tsuchimoto | CFO | $183,225 |